You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: March 29, 2024

Claims for Patent: 5,409,990


✉ Email this page to a colleague

« Back to Dashboard


Summary for Patent: 5,409,990
Title: Complex containing coagulation factor IX
Abstract:Factor IX is selectively adsorbed by means of hydrophobic chromatography from an aqueous mixture containing at least one plasma zymogen or a vitamin-K dependent protein in addition to factor IX. By this method, the efficient enrichment of factor IX for the production of pharmaceutical preparations has become possible.
Inventor(s): Linnau; Yendra (Vienna, AT), Sazgary; Maria (Vienna, AT)
Assignee: Immuno Aktiengesellschaft (Wien, AT)
Application Number:08/146,921
Patent Claims:1. A coagulation factor IX complex which comprises a carrier based on a polymer containing hydrophobic groups, to which factor IX is selectively bound from an aqueous mixture containing at least one plasma zymogen in addition to factor IX.

2. A coagulation factor IX complex which comprises a carrier based on a polymer containing hydrophobic groups, to which factor IX is selectively bound from an aqueous mixture containing at least one vitamin-K dependent protein in addition to factor IX.

3. A coagulation factor IX complex as set forth in claim 2, wherein said at least one vitamin-K dependent protein is selected from the group consisting of protein C, protein S and factors II, VII and X.

4. A complex as set forth in claim 2, wherein said factor IX is bound from an aqueous mixture containing prothrombin complex.

5. A complex as set forth in claim 2, wherein said factor IX has an activity that is at least five times higher than that of another vitamin-K dependent protein present in said aqueous mixture.

6. A complex as set forth in claim 1 treated to inactivate possibly present infectious agents.

7. A method for using a coagulation factor IX complex, comprising the steps of:

(a) providing a preparation containing coagulation factor IX complex which comprises a carrier based on a polymer containing hydrophobic groups, to which factor IX is selectively bound from an aqueous mixture containing at least one plasma zymogen in addition to factor IX, and

(b) using the complex of step (a) for obtaining monoclonal antibodies directed against factor IX.

8. A method for using a coagulation factor IX complex, comprising the steps of:

(a) providing a preparation containing coagulation factor IX complex which comprises a carrier based on a polymer containing hydrophobic groups, to which factor IX is selectively bound from an aqueous mixture containing at least one plasma zymogen in addition to factor IX, and

(b) using the complex of step (a) for obtaining polyclonal antibodies directed against factor IX.

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.